Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL4282702

Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCCc2ccc(F)cc2)CC1
ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID CHEMBL4282702
Phase Preclinical
Structure Type MOL
InChI Key UBNDBTRGSCEYOS-UHFFFAOYSA-N
14
Targets
20
Activities
2
Assay Types
0
PK Parameters
20
Publications
0
Known Names

Molecular Properties

443.9
MW (Da)
6.19
ALogP
2
HBA
1
HBD
23.5
PSA (Ų)
0.41
QED
1
Ro5 Violations
7
Rot. Bonds

Drug Information

Molecule Type Small molecule
Availability Unknown
Chirality Unknown

Flags

First in Class Prodrug

Extended Properties

Molecular Formula C23H26ClF4NO
MW 443.91
Aromatic Rings 2
Heavy Atoms 30
NP-Likeness -0.86

Activity Summary

Ki 11 meas. best 6.88
IC50 9 meas. best 5.09

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
D(4) dopamine receptor
CHEMBL219
 Ki 6.88 6.88 132.0 1
Histamine H2 receptor
CHEMBL1941
 Ki 6.4 6.4 401.0 1
D(2) dopamine receptor
CHEMBL217
 Ki 6.34 6.34 460.0 1
Mu-type opioid receptor
CHEMBL233
 Ki 6.27 6.27 536.0 1
Histamine H1 receptor
CHEMBL231
 Ki 6.14 6.14 718.0 1
5-hydroxytryptamine receptor 2A
CHEMBL224
 Ki 6.05 6.05 889.0 1
5-hydroxytryptamine receptor 1A
CHEMBL214
 Ki 6.04 6.04 901.0 1
5-hydroxytryptamine receptor 7
CHEMBL3155
 Ki 5.95 5.95 1120.0 1
Kappa-type opioid receptor
CHEMBL237
 Ki 5.77 5.77 1705.0 1
5-hydroxytryptamine receptor 2C
CHEMBL225
 Ki 5.59 5.59 2548.0 1
5-hydroxytryptamine receptor 1D
CHEMBL1983
 Ki 5.35 5.35 4431.0 1
Lewis lung carcinoma cell line
CHEMBL614088
 IC50 5.09 4.86 8200.0 3
MDA-MB-231
CHEMBL400
 IC50 5.01 4.88 9800.0 3
NIH3T3
CHEMBL614822
 IC50 5.01 4.94 9800.0 3

Activity Data Samples

Top measurements by pChEMBL value

Target Type Rel. Value Units pChEMBL Assay PubMed
D(4) dopamine receptor Ki = 132.0 nM 6.88 Displacement of [3H]N-methylspiperone from human dopamine D4 receptor by radioli... 30389290
Histamine H2 receptor Ki = 401.0 nM 6.4 Displacement of [3H]Cimetidine from human H2 receptor expressed in HEK cells by ... 30389290
D(2) dopamine receptor Ki = 460.0 nM 6.34 Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed ... 30389290
Mu-type opioid receptor Ki = 536.0 nM 6.27 Displacement of [3H]DAMGO from human MOR expressed in HEK cells by radioligand b... 30389290
Histamine H1 receptor Ki = 718.0 nM 6.14 Displacement of [3H]Pyrilamine from human H1 receptor expressed in HEK cells by ... 30389290
5-hydroxytryptamine receptor 2A Ki = 889.0 nM 6.05 Displacement of [3H]Ketanserin from 5-HT2A receptor (unknown origin) by radiolig... 30389290
5-hydroxytryptamine receptor 1A Ki = 901.0 nM 6.04 Displacement of [3H]-Way100635 from human 5HT1A receptor expressed in stable CHO... 30389290
5-hydroxytryptamine receptor 7 Ki = 1120.0 nM 5.95 Displacement of [3H]LSD from human 5-HT7A receptor expressed in HEK cells by rad... 30389290
Kappa-type opioid receptor Ki = 1705.0 nM 5.77 Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by r... 30389290
5-hydroxytryptamine receptor 2C Ki = 2548.0 nM 5.59 Displacement of [3H]Mesulergine from human 5-HT2C receptor expressed in HEK293Fl... 30389290
5-hydroxytryptamine receptor 1D Ki = 4431.0 nM 5.35 Displacement of [3H]5-CT from human 5-HT1D receptor expressed in HEK293T cells b... 30389290
Lewis lung carcinoma cell line IC50 = 8200.0 nM 5.09 Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction i... 30389290
NIH3T3 IC50 = 9800.0 nM 5.01 Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability... 30389290
MDA-MB-231 IC50 = 9800.0 nM 5.01 Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viabil... 30389290
NIH3T3 IC50 = 11800.0 nM 4.93 Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability... 30389290
Lewis lung carcinoma cell line IC50 = 11900.0 nM 4.92 Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction i... 30389290
MDA-MB-231 IC50 = 11900.0 nM 4.92 Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viabil... 30389290
NIH3T3 IC50 = 13200.0 nM 4.88 Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability... 30389290
MDA-MB-231 IC50 = 19400.0 nM 4.71 Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viabil... 30389290
Lewis lung carcinoma cell line IC50 = 26900.0 nM 4.57 Cytotoxicity against mouse LLC cells harboring luciferin assessed as reduction i... 30389290

Literature References

PubMed DOI Target Context # Activities
30389290 10.1016/j.bmcl.2018.10.036 Lewis lung carcinoma cell line 3
30389290 10.1016/j.bmcl.2018.10.036 NIH3T3 3
30389290 10.1016/j.bmcl.2018.10.036 MDA-MB-231 3
30389290 10.1016/j.bmcl.2018.10.036 Sodium-dependent dopamine transporter 2
30389290 10.1016/j.bmcl.2018.10.036 Histamine H1 receptor 2
30389290 10.1016/j.bmcl.2018.10.036 Delta-type opioid receptor 2
30389290 10.1016/j.bmcl.2018.10.036 Mu-type opioid receptor 2
30389290 10.1016/j.bmcl.2018.10.036 Kappa-type opioid receptor 2
30389290 10.1016/j.bmcl.2018.10.036 D(1B) dopamine receptor 2
30389290 10.1016/j.bmcl.2018.10.036 D(4) dopamine receptor 2
30389290 10.1016/j.bmcl.2018.10.036 D(3) dopamine receptor 2
30389290 10.1016/j.bmcl.2018.10.036 D(2) dopamine receptor 2
30389290 10.1016/j.bmcl.2018.10.036 D(1A) dopamine receptor 2
30389290 10.1016/j.bmcl.2018.10.036 5-hydroxytryptamine receptor 7 2
30389290 10.1016/j.bmcl.2018.10.036 5-hydroxytryptamine receptor 6 2
30389290 10.1016/j.bmcl.2018.10.036 5-hydroxytryptamine receptor 5A 2
30389290 10.1016/j.bmcl.2018.10.036 5-hydroxytryptamine receptor 2C 2
30389290 10.1016/j.bmcl.2018.10.036 5-hydroxytryptamine receptor 2B 2
30389290 10.1016/j.bmcl.2018.10.036 5-hydroxytryptamine receptor 2A 2
30389290 10.1016/j.bmcl.2018.10.036 5-hydroxytryptamine receptor 1D 2

Data from ChEMBL 36 via Core Engine